Literature DB >> 26962530

Vaginal Approaches Using Synthetic Mesh to Treat Pelvic Organ Prolapse.

Jei Won Moon1, Hee Dong Chae1.   

Abstract

Pelvic organ prolapse (POP) is a very common condition in elderly women. In women with POP, a sacrocolpopexy or a vaginal hysterectomy with anterior and posterior colporrhaphy has long been considered as the gold standard of treatment. However, in recent decades, the tendency to use a vaginal approach with mesh for POP surgery has been increasing. A vaginal approach using mesh has many advantages, such as its being less invasive than an abdominal approach and easier to do than a laparoscopic approach and its having a lower recurrence rate than a traditional approach. However, the advantages of a vaginal approach with mesh for POP surgery must be weighed against the disadvantages. Specific complications that have been reported when using mesh in POP procedures are mesh erosion, dyspareunia, hematomas, urinary incontinence and so on, and evidence supporting the use of transvaginal surgery with mesh is still lacking. Hence, surgeons should understand the details of the surgical pelvic anatomy, the various surgical techniques for POP surgery, including using mesh, and the possible side effects of using mesh.

Entities:  

Keywords:  Mesh; Pelvic organ prolapse

Year:  2016        PMID: 26962530      PMCID: PMC4783513          DOI: 10.3393/ac.2016.32.1.7

Source DB:  PubMed          Journal:  Ann Coloproctol        ISSN: 2287-9714


INTRODUCTION

Pelvic organ prolapse (POP) is a very common condition seen in aged women. It was reported that "the demand for care for pelvic floor disorders would increase by 35% between 2010 and 2030" in the United States [1]. The causes of POP are variable and mostly contribute to a weakening of the pelvic supportive structures, including connective tissues and muscles, and to damage of nerves nearby. Likewise, our society is an aging society, so the frequency of POP surgery is increasing. In the past, conventional abdominal or vaginal surgery was performed to treat patients with a POP. However, considering the patient's old age, when developing a new method of POP surgery using synthetic mesh, we should consider minimally invasive surgery, which has a lower risk than conventional treatment. The advantages of vaginal surgery using mesh for treating patients with a POP are as follows: it is less invasive than an abdominal approach, is easier to do than a laparoscopic approach, and has a lower recurrence rate than a traditional approach. However, in 2008 and 2011, the U.S. Food and drug Administration (FDA) released a statement alerting the public about the potentially serious complications and problems related to the use of transvaginal mesh in the treatment of patients with a POP. Ironically, after the 2008 FDA announcement, the rate of using vaginal-mesh implantation increased until 2009 [2]. Also, some researchers have different ways of thinking, and there is some dispute about the safety of using mesh [3]. Further research is needed to assess the long-term outcome, functional results, and the side effects of using vaginal mesh. Until now, the vaginal approach using mesh for the treatment of patients with a POP has shown favorable results. It may decrease morbidity and preserve (or improve) surgical cure rates. The ultimate goal of POP surgery is to correct both the anatomic and the functional derangements at the same time and to improve the quality of life (QoL) of the patients, and for this purpose, the surgeon should understand in detail the surgical pelvic anatomy, the various surgical techniques including the use of mesh, and the possible side effects of using mesh.

PELVIC ANATOMY

The pelvic anatomy may be defined as those bones, muscles, ligaments, and organs that contribute to the normal function of the pelvic floor. Normal functioning of these pelvic organs depends directly on the structural integrity of the pelvic floor. Among these, bones and connective tissue are the main structural components of the pelvis. The connective tissue consists of ligaments and fascia. The critical elements of connective tissue are collagen and elastin, both of which are changed during pregnancy, childbirth, and aging. These changes may weaken the ligaments and fascia, affecting the structural integrity of the pelvic floor. This may result in prolapse and pelvic organ dysfunction. The axis of pelvic support was suggested by DeLancey (Fig. 1) [45]. Level I is the upper vertical axis, which suspends the upper vagina and cervix from the lateral pelvic wall. Level II is the horizontal axis that leads to lateral and paravaginal support. Level III is the lower vertical axis, and it supports the lower third of the vagina, the urethra and the anal canal [45]. Three-directional muscle forces, the anterior portion of the pubococcygeus muscle, the levator plate, and the longitudinal muscle of the anus activate urethral and anal canal closure and help retain the positions of the organs. The levator plate and the longitudinal muscle of the anus open both the urethra during micturition when the pubococcygeus muscle relaxes and the anal canal during defecation when the puborectalis muscle relaxes. Especially, the middle portion of the vagina, level II by DeLancey [45], is supported by the endopelvic fascia. It attaches the vagina laterally and more directly to the pelvic wall, and this attachment stretches the vagina transversely between the bladder and the rectum and has functional significance. The endopelvic fascia is attached laterally to the arcus tendineus fascia pelvis. The arcus tendineus fascia pelvis is a thickening of the parietal fascia of the levator ani muscle and travels from the pubic arch in a straight line to the ischial spine; it is approximately 8–10 cm in length.
Fig. 1

Axis of pelvic support. Adapted from Korean Society of Obstetric and Gynecology, editor. Gynecology. 5th ed. 2015. Fig. 43-6; p. 1120, with permission of Korean Society of Obstetric and Gynecology [5].

The bony pelvis is not important to the support of the pelvic organs for preventing prolapse, but several structures are very important for POP surgery: the ischial spine, the obturator foramen, the sacrospinous ligament, and the sacrotuberous ligament. The internal pudendal artery from the internal iliac artery and the pudendal nerve pass the greater and the lesser sciatic foramen around the ischial spine, and because this area is the penetration site for suspension during prolapse surgery using mesh, we should be careful during the operation (Fig. 2) [6]. Understanding the pelvic anatomy and the supporting structures as described above is very important for surgical treatment of a POP.
Fig. 2

Blood supply and nerve distribution in the pelvis. Adapted from Korean Society of Obstetric and Gynecology, editor. Gynecology. 5th ed. 2015. Fig. 2-3, 2-5; p. 18, 20, with permission of Korean Society of Obstetric and Gynecology [6].

TREATMENTS

To treat patients with a POP, the surgeon should always consider the patient's age, the patient's desire for childbearing, the severity of the patient's symptoms, which might have an impact on the patient's QoL, the patient's desire for coital function, and the presence of other medical morbidities. After the patient's overall condition has been considered, a thoughtful decision should be made concerning the treatment of the POP, which includes nonsurgical and surgical treatments. Nonsurgical methods include lifestyle modification (weight loss and reduction of those activities that increase intra-abdominal pressure), pelvic floor muscle training such as Kegel exercise, and the use of mechanical devices. However, conservative management can only be helpful for patients with a lower POP stage according to the pelvic organ prolapse quantification system (POP-Q) [7]. The purposes of conservative treatment are to avoid or delay surgery because of old age, to reduce surgical risks, to increase muscle strength, and to prevent worsening of the symptoms. Correcting the prolapsed vagina, while maintaining sexual function and relieving associated pelvic symptoms, is important. Many techniques have been described for POP surgeries, but unfortunately, few studies have attempted to identify the optimal surgical approach. In upper vaginal prolapse (uterine or vaginal vault prolapse), a vaginal hysterectomy with an anterior and posterior colporrhaphy, an abdominal (laparotomic, laparoscopic, or robotic) sacrocolpopexy, and a uterosacral or sacrospinous ligament suspension have been used. For an anterior or posterior vaginal wall prolapse, an anterior or posterior colporrhaphy with or without graft reinforcement should be considered. Mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue, fascia, or bone where weakness exists. There are synthetic and biological meshes, and biological grafts can be classified as allografts, autografts or xenografts. Synthetic meshes differ in absorbability (nonabsorbable vs. absorbable), composition (monofilament vs. multifilament), pore size, flexibility, and architecture (knitted or woven) [8]. In synthetic grafts, polypropylene mesh of a monofilament, macroporous type is most commonly used; however, the use of polypropylene mesh may cause a strong foreign body reaction, and healing may be adversely affected when such a reaction occurs. Recently, a partially-absorbable mesh has been used, and compared with nonabsorbable mesh, it seems to have a lower exposure rate [910]. Mesh should be sterile and noncarcinogenic, produce no inflammatory reaction, and be easy to use, nonallergenic, and resistant to infection, but unfortunately, as of now, no such ideal mesh exists. Petros performed intravaginal sling-plasties using mesh for the first time (Fig. 3) [11]. Seventy-five women with at least a second-degree vaginal vault prolapse after abdominal or vaginal hysterectomy were included. The success rate of that study was 94%, and a 5.6% mesh erosion rate was reported. After the advent of the total vaginal polypropylene mesh kit, POP management has experienced a complete change. Many studies have shown acceptable cure rates with low morbidity rates [12]. A recent randomized, prospective, controlled study showed that using transvaginal mesh in the treatment of a posthysterectomy vaginal vault prolapse had a lower recurrence rate than surgery with sacrospinous fixation did [13]. In that study, the sacrospinous fixation group had a higher recurrence rate (28 of 72, 39%) than transvaginal mesh group did (13 of 79, 17%). Reoperation for prolapse was performed in 3 out of the 72 patients in the sacrospinous fixation group and in 1 out of the 79 patients in the transvaginal mesh group. No differences in the de novo stress urinary incontinence (SUI), bladder overactivity, dyspareunia, pelvic pain and QoL improvement were identified between the 2 groups. However, the mesh exposure rate has been reported to be 20.8%, and several retrospective studies have shown anatomical cure rates of 81.2%–89.9% when transvaginal mesh kits are used for the treatment of patients with a POP [14]. Surprisingly, one retrospective study from Canada showed 97.4% of overall success rate, with a small mesh extrusion in only 1 patient, when light-weight polypropylene mesh was used to repair the POP [15].
Fig. 3

Transvaginal surgical approach using mesh to treat a pelvic organ prolapse. Adapted from Serag Wiessner (Naila, Germany), with permission.

Two recent randomized, controlled trial comparing traditional colporrhaphy and transvaginal polypropylene mesh for the treatment of patients with an advanced anterior vaginal prolapse showed that transvaginal polypropylene mesh surgery had higher anatomical success and satisfaction rates compared with traditional colporrhaphy [16]. A similar randomized, controlled trial concluded that trocar-guided transvaginal synthetic mesh for advanced anterior POP repair had a higher success rate than traditional colporrhaphy with a 5% mesh erosion rate [17]. Many other studies have demonstrated that compared with native tissue repairs, transvaginal synthetic mesh surgery decreases the incidence of prolapse recurrence in the anterior compartment [18]. Although transvaginal synthetic mesh surgery has the benefits of low rates of prolapse recurrence and high satisfaction rates after the procedure, several complications are associated with transvaginal synthetic mesh surgery. In 2011, the US FDA had a consensus meeting to update the safety and the effectiveness of transvaginal placement for the treatment of patients with a POP. The most common complications of the mesh were reported to be mesh exposure, pelvic pain, infection, bleeding, dyspareunia, and organ perforation [19]. Additionally, contrary to our expectations, regarding rates of reintervention, a newly-developed partially-absorbable mesh does not seem to give any advantage in reducing mesh exposure, recurrence, urinary complication and dyspareunia in comparison with classic nonabsorbable mesh [20]. However, some risk factors for mesh erosion can be reduced. Surgical factors are improper mesh placement, inverted T-incision, vaginal-wall trimming, total application of mesh, and surgeon's experience or skill. Host factors are smoking, obesity, poorly controlled diabetes mellitus, urogenital atrophy, prior pelvic radiation, and current steroid use. Surgeons should undergo surgical training and acquire a full understanding of the role of mesh before using a vaginal approach with mesh for POP surgery. Nevertheless, vaginal mesh is an important tool in surgical armamentarium and may be the best options in some patients with a POP, especially those with an anterior compartment POP, a recurrent POP, an advanced POP or significant medical comorbidities in whom an invasive sacrocolpopexy procedure may be contraindicated [21].

CONCLUSION

The best approach to POP surgery remains controversial. However, a vaginal approach using mesh for the treatment of a POP may improve the surgical cure rate and decrease the burden of invasive surgery on the patient. The main purpose of using mesh is to achieve both anatomical recovery and improved QoL. When mesh is being considered for POP surgery, each patient must be carefully evaluated on an individual basis, and informed consent based on the latest information available in the literature must be obtained. The use of vaginal mesh should be limited to a carefully selected population. Surgeons should choose mesh surgery only after weighing the risks and the benefits of surgery with mesh versus all surgical and nonsurgical alternatives, notify the patient that mesh will be used in the POP surgery, and provide the patient with information on the risks associated with the use of mesh, such as complications and limited long-term outcomes.
  19 in total

1.  The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.

Authors:  R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

Review 2.  Synthetic vaginal mesh for pelvic organ prolapse.

Authors:  Cheryl B Iglesia
Journal:  Curr Opin Obstet Gynecol       Date:  2011-10       Impact factor: 1.927

3.  Outcomes and complications of trans-vaginal mesh repair using the Prolift™ kit for pelvic organ prolapse at 4 years median follow-up in a tertiary referral centre.

Authors:  Zainab A Khan; Lee Thomas; Simon J Emery
Journal:  Arch Gynecol Obstet       Date:  2014-07-01       Impact factor: 2.344

4.  Rate of re-interventions after transvaginal pelvic organ prolapse repair using partially absorbable mesh: 20 months median follow-up outcomes.

Authors:  Julie Quemener; Nicolas Joutel; Jean-Philippe Lucot; Géraldine Giraudet; Pierre Collinet; Chrystèle Rubod; Michel Cosson
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2014-01-03       Impact factor: 2.435

5.  Two-years results of native tissue versus vaginal mesh repair in the treatment of anterior prolapse according to different success criteria: A randomized controlled trial.

Authors:  Márcia M Dias; Rodrigo de A Castro; Maria Augusta T Bortolini; Carlos A Delroy; Paulo C F Martins; Manoel J B C Girão; Marair G F Sartori
Journal:  Neurourol Urodyn       Date:  2015-03-27       Impact factor: 2.696

6.  Lower exposure rates of partially absorbable mesh compared to nonabsorbable mesh for cystocele treatment: 3-year follow-up of a prospective randomized trial.

Authors:  J Farthmann; D Watermann; A Niesel; C Fünfgeld; A Kraus; F Lenz; H J Augenstein; E Graf; B Gabriel
Journal:  Int Urogynecol J       Date:  2012-08-29       Impact factor: 2.894

7.  Outcomes and complications of transvaginal and abdominal custom-shaped light-weight polypropylene mesh used in repair of pelvic organ prolapse.

Authors:  E J Stanford; T F Mattox; C J Pugh
Journal:  J Minim Invasive Gynecol       Date:  2010-10-20       Impact factor: 4.137

8.  Attitudes toward transvaginal mesh among patients in a urogynecology practice.

Authors:  Sybil G Dessie; Michele R Hacker; Miriam J Haviland; Peter L Rosenblatt
Journal:  Int Urogynecol J       Date:  2015-01-17       Impact factor: 2.894

9.  Retrospective multicentre study of the new minimally invasive mesh repair devices for pelvic organ prolapse.

Authors:  M Abdel-Fattah; I Ramsay
Journal:  BJOG       Date:  2008-01       Impact factor: 6.531

10.  The use of transvaginal synthetic mesh for anterior vaginal wall prolapse repair: a randomized controlled trial.

Authors:  Carlos A Delroy; Rodrigo de A Castro; Márcia M Dias; Paulo C Feldner; Maria Augusta T Bortolini; Manoel J B C Girão; Marair G F Sartori
Journal:  Int Urogynecol J       Date:  2013-04-30       Impact factor: 2.894

View more
  2 in total

1.  Functional outcomes of synthetic tape and mesh revision surgeries: a monocentric experience.

Authors:  Salima Ismail; Emmanuel Chartier-Kastler; Christine Reus; Jérémy Cohen; Thomas Seisen; Véronique Phé
Journal:  Int Urogynecol J       Date:  2018-08-01       Impact factor: 2.894

2.  Effects of mesh surgery on sexual function in pelvic prolapse and urinary incontinence.

Authors:  Gökmen Sukgen; Adem Altunkol; Ayşe Yiğit
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.